Trial Watch: Peptide vaccines in cancer therapy
Throughout the past 3 decades, along with the recognition that the immune system not only influences oncogenesis and tumor progression, but also determines how established neoplastic lesions respond therapy, renovated enthusiasm has gathered around the possibility of using vaccines as anticancer age...
| Autores: | , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2013 |
| País: | España |
| Institución: | Universidad de Navarra |
| Repositorio: | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Idioma: | inglés |
| OAI Identifier: | oai:dadun.unav.edu:10171/120183 |
| Acceso en línea: | https://hdl.handle.net/10171/120183 |
| Access Level: | acceso abierto |
| Palabra clave: | Adjuvants Dendritic cells Ipilimumab NY-ESO-1 Survivin TLR agonists |
| id |
ES_17dd7848e9e132a0bf8a111c4bbbabd2 |
|---|---|
| oai_identifier_str |
oai:dadun.unav.edu:10171/120183 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Trial Watch: Peptide vaccines in cancer therapyAranda-Vega, F. (Fernando)|||/items/967c4675-0318-4d3c-97dc-b5b09026995fVacchelli, E. (Erika)|||/items/1db2a15b-f58b-4abf-833e-3785f69eb053Eggermont, A.M. (Alexander M.)|||/items/d3a7f6a5-500d-4855-bde6-8fccf21aad37Galon, J. (Jerome)|||/items/6a1adda1-b579-4f93-9a3d-5a8c7fc03939Sautès-Fridman, C. (Catherine)|||/items/861ea7f2-0e92-4dd5-bb78-65169622fb43Tartour, E. (Eric)|||/items/f3b1d85b-6bd5-446b-aad2-9cc79975059eZitvogel, L. (Laurence)|||/items/ad85ff59-7ca2-4f87-8931-a921648eb97bKroemer, G. (Guido)|||/items/ae5c18f3-0594-4a44-b71d-a367305f464fGalluzzi, L. (Lorenzo)|||/items/a8408d1f-8344-4d64-82a7-a8775587ef8dAdjuvantsDendritic cellsIpilimumabNY-ESO-1SurvivinTLR agonistsThroughout the past 3 decades, along with the recognition that the immune system not only influences oncogenesis and tumor progression, but also determines how established neoplastic lesions respond therapy, renovated enthusiasm has gathered around the possibility of using vaccines as anticancer agents. Such an enthusiasm quickly tempered when it became clear that anticancer vaccines would have to be devised as therapeutic, rather than prophylactic, measures, and that malignant cells often fail to elicit (or actively suppress) innate and adaptive immune responses. Nonetheless, accumulating evidence indicates that a variety of anticancer vaccines, including cell-based, DNA-based, and purified component-based preparations, are capable of circumventing the poorly immunogenic and highly immunosuppressive nature of most tumors and elicit (at least under some circumstances) therapeutically relevant immune responses. Great efforts are currently being devoted to the identification of strategies that may provide anticancer vaccines with the capacity of breaking immunological tolerance and eliciting tumor-associated antigen-specific immunity in a majority of patients. In this sense, promising results have been obtained by combining anticancer vaccines with a relatively varied panels of adjuvants, including multiple immunostimulatory cytokines, Toll-like receptor agonists as well as inhibitors of immune checkpoints. One year ago, in the December issue of OncoImmunology, we discussed the biological mechanisms that underlie the antineoplastic effects of peptide-based vaccines and presented an abundant literature demonstrating the prominent clinical potential of such an approach. Here, we review the latest developments in this exciting area of research, focusing on high-profile studies that have been published during the last 13 mo and clinical trials launched in the same period to evaluate purified peptides or full-length proteins as therapeutic anticancer agents.Taylor & Francis GroupDadun. Depósito Académico Digital Universidad de Navarra20132013-01-0120132013-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/120183reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/1201832026-06-21T12:47:57Z |
| dc.title.none.fl_str_mv |
Trial Watch: Peptide vaccines in cancer therapy |
| title |
Trial Watch: Peptide vaccines in cancer therapy |
| spellingShingle |
Trial Watch: Peptide vaccines in cancer therapy Aranda-Vega, F. (Fernando)|||/items/967c4675-0318-4d3c-97dc-b5b09026995f Adjuvants Dendritic cells Ipilimumab NY-ESO-1 Survivin TLR agonists |
| title_short |
Trial Watch: Peptide vaccines in cancer therapy |
| title_full |
Trial Watch: Peptide vaccines in cancer therapy |
| title_fullStr |
Trial Watch: Peptide vaccines in cancer therapy |
| title_full_unstemmed |
Trial Watch: Peptide vaccines in cancer therapy |
| title_sort |
Trial Watch: Peptide vaccines in cancer therapy |
| dc.creator.none.fl_str_mv |
Aranda-Vega, F. (Fernando)|||/items/967c4675-0318-4d3c-97dc-b5b09026995f Vacchelli, E. (Erika)|||/items/1db2a15b-f58b-4abf-833e-3785f69eb053 Eggermont, A.M. (Alexander M.)|||/items/d3a7f6a5-500d-4855-bde6-8fccf21aad37 Galon, J. (Jerome)|||/items/6a1adda1-b579-4f93-9a3d-5a8c7fc03939 Sautès-Fridman, C. (Catherine)|||/items/861ea7f2-0e92-4dd5-bb78-65169622fb43 Tartour, E. (Eric)|||/items/f3b1d85b-6bd5-446b-aad2-9cc79975059e Zitvogel, L. (Laurence)|||/items/ad85ff59-7ca2-4f87-8931-a921648eb97b Kroemer, G. (Guido)|||/items/ae5c18f3-0594-4a44-b71d-a367305f464f Galluzzi, L. (Lorenzo)|||/items/a8408d1f-8344-4d64-82a7-a8775587ef8d |
| author |
Aranda-Vega, F. (Fernando)|||/items/967c4675-0318-4d3c-97dc-b5b09026995f |
| author_facet |
Aranda-Vega, F. (Fernando)|||/items/967c4675-0318-4d3c-97dc-b5b09026995f Vacchelli, E. (Erika)|||/items/1db2a15b-f58b-4abf-833e-3785f69eb053 Eggermont, A.M. (Alexander M.)|||/items/d3a7f6a5-500d-4855-bde6-8fccf21aad37 Galon, J. (Jerome)|||/items/6a1adda1-b579-4f93-9a3d-5a8c7fc03939 Sautès-Fridman, C. (Catherine)|||/items/861ea7f2-0e92-4dd5-bb78-65169622fb43 Tartour, E. (Eric)|||/items/f3b1d85b-6bd5-446b-aad2-9cc79975059e Zitvogel, L. (Laurence)|||/items/ad85ff59-7ca2-4f87-8931-a921648eb97b Kroemer, G. (Guido)|||/items/ae5c18f3-0594-4a44-b71d-a367305f464f Galluzzi, L. (Lorenzo)|||/items/a8408d1f-8344-4d64-82a7-a8775587ef8d |
| author_role |
author |
| author2 |
Vacchelli, E. (Erika)|||/items/1db2a15b-f58b-4abf-833e-3785f69eb053 Eggermont, A.M. (Alexander M.)|||/items/d3a7f6a5-500d-4855-bde6-8fccf21aad37 Galon, J. (Jerome)|||/items/6a1adda1-b579-4f93-9a3d-5a8c7fc03939 Sautès-Fridman, C. (Catherine)|||/items/861ea7f2-0e92-4dd5-bb78-65169622fb43 Tartour, E. (Eric)|||/items/f3b1d85b-6bd5-446b-aad2-9cc79975059e Zitvogel, L. (Laurence)|||/items/ad85ff59-7ca2-4f87-8931-a921648eb97b Kroemer, G. (Guido)|||/items/ae5c18f3-0594-4a44-b71d-a367305f464f Galluzzi, L. (Lorenzo)|||/items/a8408d1f-8344-4d64-82a7-a8775587ef8d |
| author2_role |
author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Dadun. Depósito Académico Digital Universidad de Navarra |
| dc.subject.none.fl_str_mv |
Adjuvants Dendritic cells Ipilimumab NY-ESO-1 Survivin TLR agonists |
| topic |
Adjuvants Dendritic cells Ipilimumab NY-ESO-1 Survivin TLR agonists |
| description |
Throughout the past 3 decades, along with the recognition that the immune system not only influences oncogenesis and tumor progression, but also determines how established neoplastic lesions respond therapy, renovated enthusiasm has gathered around the possibility of using vaccines as anticancer agents. Such an enthusiasm quickly tempered when it became clear that anticancer vaccines would have to be devised as therapeutic, rather than prophylactic, measures, and that malignant cells often fail to elicit (or actively suppress) innate and adaptive immune responses. Nonetheless, accumulating evidence indicates that a variety of anticancer vaccines, including cell-based, DNA-based, and purified component-based preparations, are capable of circumventing the poorly immunogenic and highly immunosuppressive nature of most tumors and elicit (at least under some circumstances) therapeutically relevant immune responses. Great efforts are currently being devoted to the identification of strategies that may provide anticancer vaccines with the capacity of breaking immunological tolerance and eliciting tumor-associated antigen-specific immunity in a majority of patients. In this sense, promising results have been obtained by combining anticancer vaccines with a relatively varied panels of adjuvants, including multiple immunostimulatory cytokines, Toll-like receptor agonists as well as inhibitors of immune checkpoints. One year ago, in the December issue of OncoImmunology, we discussed the biological mechanisms that underlie the antineoplastic effects of peptide-based vaccines and presented an abundant literature demonstrating the prominent clinical potential of such an approach. Here, we review the latest developments in this exciting area of research, focusing on high-profile studies that have been published during the last 13 mo and clinical trials launched in the same period to evaluate purified peptides or full-length proteins as therapeutic anticancer agents. |
| publishDate |
2013 |
| dc.date.none.fl_str_mv |
2013 2013-01-01 2013 2013-01-01 |
| dc.type.none.fl_str_mv |
journal article http://purl.org/coar/resource_type/c_6501 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/10171/120183 |
| url |
https://hdl.handle.net/10171/120183 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Taylor & Francis Group |
| publisher.none.fl_str_mv |
Taylor & Francis Group |
| dc.source.none.fl_str_mv |
reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Universidad de Navarra |
| instname_str |
Universidad de Navarra |
| reponame_str |
Dadun. Depósito Académico Digital de la Universidad de Navarra |
| collection |
Dadun. Depósito Académico Digital de la Universidad de Navarra |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869403948098519040 |
| score |
15,811543 |